Segall Bryant & Hamill’s Alnylam Pharmaceuticals ALNY Stock Holding History

Segall Bryant & Hamill’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,000	Closed	-$380K	–	516
2023 Q2	$380K	Hold	2,000	–	–	﹤0.01%	606
2023 Q1	$400K	Hold	2,000	–	–	﹤0.01%	601
2022 Q4	$475K	Hold	2,000	–	–	0.01%	579
2022 Q3	$400K	Hold	2,000	–	–	﹤0.01%	611
2022 Q2	$292K	Hold	2,000	–	–	﹤0.01%	664
2022 Q1	$327K	Hold	2,000	–	–	﹤0.01%	668
2021 Q4	$339K	Hold	2,000	–	–	﹤0.01%	539
2021 Q3	$378K	Hold	2,000	–	–	﹤0.01%	665
2021 Q2	$339K	Sell	2,000 -9	-0.4%	-$1.32K	﹤0.01%	673
2021 Q1	$283K	Hold	2,009	–	–	﹤0.01%	737
2020 Q4	$261K	Hold	2,009	–	–	﹤0.01%	672
2020 Q3	$292K	Buy	2,009 +9	+0.5%	+$1.28K	﹤0.01%	625
2020 Q2	$296K	Hold	2,000	–	–	0.01%	683
2020 Q1	$218K	Hold	2,000	–	–	﹤0.01%	728
2019 Q4	$230K	Buy	+2,000	New	+$199K	﹤0.01%	773
2018 Q2	–	Sell	-2,000	Closed	-$238K	–	854
2018 Q1	$238K	Hold	2,000	–	–	0.01%	562
2017 Q4	$254K	Hold	2,000	–	–	0.01%	520
2017 Q3	$235K	Buy	+2,000	New	+$171K	0.01%	530
2015 Q3	–	Sell	-2,000	Closed	-$240K	–	544
2015 Q2	$240K	Hold	2,000	–	–	0.01%	510
2015 Q1	$209K	Buy	+2,000	New	+$203K	﹤0.01%	533

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Segall Bryant & Hamill's ALNY Position: Q3 2023 in Review

Segall Bryant & Hamill sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2023, closing a stake of 2,000 shares — an estimated $380K sold.

Segall Bryant & Hamill first reported a position in ALNY in Q1 2015 and held it in 20 quarters. The position peaked at $475K in Q4 2022. 453 funds tracked by Wall St. Rank hold ALNY as of Q3 2023.

Segall Bryant & Hamill reported no remaining Alnylam Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Segall Bryant & Hamill sold 2,000 Alnylam Pharmaceuticals shares in Q3 2023, an estimated $380K.
Segall Bryant & Hamill first reported a position in Alnylam Pharmaceuticals in Q1 2015 and held it in 20 quarters.
Segall Bryant & Hamill's Alnylam Pharmaceuticals position peaked at $475K in Q4 2022.
453 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2023.

Based on Segall Bryant & Hamill's 13F filing for Q3 2023, filed 9 Nov 2023.